An Open Science approach to drug development – Prof. Dr. Charles Raison, MD
An Open Science approach to drug development
Science advances more from collaboration than competition. In the burgeoning field of psychedelic research, we purport that openness, transparency, and collaboration will move this field of scientific knowledge forward most efficiently and honorably. However, given the perceived need for protection of intellectual property, the economics of drug development can make such collaborative efforts challenging or pragmatically impossible. It is in this context that an open science approach to drug development and commercialization offers promise as a new paradigm for the field as a whole. Publication of scientific discoveries and processes dramatically expand the potential for future innovation while documenting existing knowledge for the public good.
This talk will highlight several examples of how a unique approach to drug development, through an open science platform is currently advancing the field of psychedelic research to enable clinical and non-clinical studies in a diverse range of indications. This approach allows researchers the freedom to conduct studies addressing clinical questions of immediate import and to investigate theoretical and basic science questions that may enrich the future of the field in ways we cannot currently envision within the constraints of the current drug development paradigm.
———
Many questions remain, join INSIGHT 2023, help us come to real solutions, and shape the future of mental health and human development:
https://insight-conference.eu/
All INSIGHT 2021 talks and panels are now publicly available on the MIND Community Platform.
Sign up on the network and become part of our community of professionals, students, and friends.
MIND Community Platform: https://community.mind-foundation.org
INSIGHT 2021 Replays: https://community.mind-foundation.org
An Open Science approach to drug development
Science advances more from collaboration than competition. In the burgeoning field of psychedelic research, we purport that openness, transparency, and collaboration will move this field of scientific knowledge forward most efficiently and honorably. However, given the perceived need for protection of intellectual property, the economics of drug development can make such collaborative efforts challenging or pragmatically impossible. It is in this context that an open science approach to drug development and commercialization offers promise as a new paradigm for the field as a whole. Publication of scientific discoveries and processes dramatically expand the potential for future innovation while documenting existing knowledge for the public good.
This talk will highlight several examples of how a unique approach to drug development, through an open science platform is currently advancing the field of psychedelic research to enable clinical and non-clinical studies in a diverse range of indications. This approach allows researchers the freedom to conduct studies addressing clinical questions of immediate import and to investigate theoretical and basic science questions that may enrich the future of the field in ways we cannot currently envision within the constraints of the current drug development paradigm.
———
Many questions remain, join INSIGHT 2023, help us come to real solutions, and shape the future of mental health and human development:
https://insight-conference.eu/
All INSIGHT 2021 talks and panels are now publicly available on the MIND Community Platform.
Sign up on the network and become part of our community of professionals, students, and friends.
MIND Community Platform: https://community.mind-foundation.org
INSIGHT 2021 Replays: https://community.mind-foundation.org
){kind=link}
Comments